Pharmacoeconomic review report Dapagliflozin (Forxiga)
Dapagliflozin (Forxiga) is an oral antihyperglycemic drug of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor class. This CADTH Common Drug Review (CDR) focuses on dapagliflozin for the treatment of patients with type 2 diabetes mellitus (T2DM) to improve glycemic control when added on to metfor...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2016.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820270506719 |
| Sumario: | Dapagliflozin (Forxiga) is an oral antihyperglycemic drug of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor class. This CADTH Common Drug Review (CDR) focuses on dapagliflozin for the treatment of patients with type 2 diabetes mellitus (T2DM) to improve glycemic control when added on to metformin and a sulfonylurea for patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea and for whom insulin is not an option. |
|---|---|
| Descripción Física: | 1 online resource |
